Literature DB >> 9208093

Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry.

A K Ganguly1, B N Pramanik, E C Huang, S Liberles, L Heimark, Y H Liu, A Tsarbopoulos, R J Doll, A G Taveras, S Remiszewski, M E Snow, Y S Wang, B Vibulbhan, D Cesarz, J E Brown, J del Rosario, L James, P Kirschmeier, V Girijavallabhan.   

Abstract

MS based methodology employing electrospray ionization (ESI) is described for the detection of ternary complexes in which SCH 54292 or SCH 54341 and GDP are noncovalently bound to oncogenic ras protein. The observed molecular weights of 19,816 and 19,570 Da confirmed the presence of noncovalent complexes of ras-GDP-SCH 54292 and ras-GDP-SCH 54341, respectively. We have also performed selective chemical modification of lysine residues of the ras protein complex followed by enzymatic digestion and on-line LC-ESI MS peptide mapping to determine protein-drug binding topography. There was a good correlation between nucleotide exchange inhibition as determined by the enzyme assay and evidence of complex formation as determined by MS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208093     DOI: 10.1016/s0968-0896(97)00021-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Authors:  Till Maurer; Lindsay S Garrenton; Angela Oh; Keith Pitts; Daniel J Anderson; Nicholas J Skelton; Benjamin P Fauber; Borlan Pan; Shiva Malek; David Stokoe; Mary J C Ludlam; Krista K Bowman; Jiansheng Wu; Anthony M Giannetti; Melissa A Starovasnik; Ira Mellman; Peter K Jackson; Joachim Rudolph; Weiru Wang; Guowei Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 2.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors:  Jonathan M L Ostrem; Kevan M Shokat
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

3.  Evaluation of complexation of metal-mediated DNA-binding drugs to oligonucleotides via electrospray ionization mass spectrometry.

Authors:  M L Reyzer; J S Brodbelt; S M Kerwin; D Kumar
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

4.  The centaurin gamma-1 GTPase-like domain functions as an NTPase.

Authors:  Meera Soundararajan; Xiaowen Yang; Jonathan M Elkins; Frank Sobott; Declan A Doyle
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

5.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

Review 6.  Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.

Authors:  Jun Zhang; Dongkyoo Park; Dong M Shin; Xingming Deng
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-11-17       Impact factor: 3.848

7.  Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer.

Authors:  Xiaoyu Guo; Wenjing Zhao; Zuojia Liu; Jin Wang
Journal:  Oncotarget       Date:  2018-01-08

8.  Overcoming Resistance to Drugs Targeting KRASG12C Mutation.

Authors:  Delong Jiao; Shengyu Yang
Journal:  Innovation (Camb)       Date:  2020-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.